Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing
Wenhua Jiang,
Hailong Wang,
Shiyong Zhou,
Guoqing Zhu,
Mingyou Gao,
Kuo Zhao,
Limeng Zhang,
Xiaojing Xie,
Ning Zhao,
Caijuan Tian,
Zhenzhen Zhang,
Fang Yan,
Yi Pan,
Pengfei Liu
Affiliations
Wenhua Jiang
Department of Radiotherapy, The Second Hospital of Tianjin Medical University
Hailong Wang
Department of Oncology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Shiyong Zhou
Department of Lymphoma, Sino-US Center of Lymphoma and Leukemia, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital
Guoqing Zhu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Mingyou Gao
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Kuo Zhao
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Limeng Zhang
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Xiaojing Xie
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Ning Zhao
Department of Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Caijuan Tian
Tianjin Marvel Medical Laboratory, Tianjin Marvelbio Technology Co., Ltd
Zhenzhen Zhang
Tianjin Marvel Medical Laboratory, Tianjin Marvelbio Technology Co., Ltd
Fang Yan
Tianjin Marvel Medical Laboratory, Tianjin Marvelbio Technology Co., Ltd
Yi Pan
Department of Pathology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital
Pengfei Liu
Department of Oncology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Abstract Background The purpose of this study was to construct a new typing model for diffuse large B-cell lymphoma (DLBCL) patients based on the B-cell receptor (BCR) and explore its potential molecular mechanism. Methods BCR repertoire sequencing and whole-exome sequencing were performed on formalin-fixed paraffin-embedded samples from 12 DLBCL patients. Subsequently, a typing model was built with cluster analysis, and prognostic indicators between the two groups were compared to verify the typing model. Then, mutation and bioinformatics analyses were conducted to investigate the potential biomarkers of prognostic differences between the two groups. Results Based on BCR sequencing data, we divided patients into two clusters (cluster 1 and cluster 2); this classification differed from the traditional typing method (GCB and non-GCB), in which cluster 1 included some non-GCB patients. The progression-free survival (PFS), overall survival (OS), metastasis and Shannon diversity index of IGH V-J and survival after chemotherapy were significantly different (P < 0.05) between the two clusters, but no statistical significance was found between the GCB and non-GCB groups. The mutation status of 248 genes was significantly different between cluster 1 and cluster 2. Among them, FTSJ3, MAGED2, and ODF3L2 were the specific mutated genes in all patients in cluster 2, and these genes could be considered critical to the different prognoses of the two clusters of DLBCL patients. Conclusion We constructed a new typing model of DLBCL based on BCR repertoire sequencing that can better predict the survival time after chemotherapy. FTSJ3, MAGED2, and ODF3L2 may represent key genes for the difference in prognosis between the two clusters.